CVRX CVRx, Inc.

Nasdaq cvrx.com


$ 10.00 $ 0.44 (4.63 %)    

Friday, 17-Oct-2025 17:43:34 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 9.95
$ 9.41
$ 6.90 x 1
$ 10.40 x 100
$ 9.41 - $ 10.12
$ 4.30 - $ 18.55
308,385
na
260.21M
$ 1.38
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2025 06-30-2025 10-Q
2 05-09-2025 03-31-2025 10-Q
3 02-18-2025 12-31-2024 10-K
4 11-01-2024 09-30-2024 10-Q
5 08-02-2024 06-30-2024 10-Q
6 05-10-2024 03-31-2024 10-Q
7 02-09-2024 12-31-2023 10-K
8 10-31-2023 09-30-2023 10-Q
9 08-03-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 02-10-2023 12-31-2022 10-K
12 11-04-2022 09-30-2022 10-Q
13 08-01-2022 06-30-2022 10-Q
14 05-02-2022 03-31-2022 10-Q
15 02-22-2022 12-31-2021 10-K
16 11-08-2021 09-30-2021 10-Q
17 08-09-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 cantor-fitzgerald-reiterates-overweight-on-cvrx-maintains-11-price-target

Cantor Fitzgerald analyst Ross Osborn reiterates CVRx (NASDAQ:CVRX) with a Overweight and maintains $11 price target.

 cvrx-sees-q3-sales-13700m-14700m-vs-14537m-est

CVRx (NASDAQ:CVRX) sees Q3 sales of $13.700 million-$14.700 million vs $14.537 million analyst estimate.

 cvrx-narrows-fy2025-sales-guidance-from-55000m-58000m-to-55000m-57000m-vs-56086m-est

CVRx (NASDAQ:CVRX) narrows FY2025 sales outlook from $55.000 million-$58.000 million to $55.000 million-$57.000 million vs $56....

 cvrx-q2-eps-057-misses-053-estimate-sales-13589m-beat-13217m-estimate

CVRx (NASDAQ:CVRX) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.53) by 7.5...

 cvrxs-barostim-implant-set-for-45k-medicare-reimbursement-under-proposed-outpatient-rule

CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, announced today that the Centers for Medi...

 piper-sandler-maintains-overweight-on-cvrx-lowers-price-target-to-12

Piper Sandler analyst Matt O'Brien maintains CVRx (NASDAQ:CVRX) with a Overweight and lowers the price target from $20 t...

 jp-morgan-downgrades-cvrx-to-underweight-lowers-price-target-to-7

JP Morgan analyst Robbie Marcus downgrades CVRx (NASDAQ:CVRX) from Neutral to Underweight and lowers the price target from $...

 cvrx-lowers-fy2025-sales-guidance-from-6300m-6500m-to-5500m-5800m-vs-6143m-est

CVRx (NASDAQ:CVRX) lowers FY2025 sales outlook from $63.00 million-$65.00 million to $55.00 million-$58.00 million vs $61.43 mi...

 cvrx-q1-eps-053-beats-056-estimate-sales-1230m-miss-1338m-estimate

CVRx (NASDAQ:CVRX) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(0.56) by 5.36 ...

 lake-street-maintains-buy-on-cvrx-lowers-price-target-to-14

Lake Street analyst Frank Takkinen maintains CVRx (NASDAQ:CVRX) with a Buy and lowers the price target from $19 to $14.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION